Icatibant Teva

Icatibant, the active ingredient in Icatibant Teva, is a bradykinin B2 receptor antagonist presented as an injectable solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema type I and type II in patients who experience rapid swelling of the skin, gastrointestinal tract, or airway.

GNH USA supplies Icatibant Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Icatibant is used to treat hereditary angioedema by targeting the bradykinin pathway.

Hereditary angioedema type I: administration of Icatibant leads to rapid reversal of edema by blocking bradykinin‑mediated vascular leakage, thereby reducing swelling of the skin, gastrointestinal tract and airway within minutes to hours. Hereditary angioedema type II: the drug similarly antagonizes bradykinin B2 receptors, providing prompt relief of swelling episodes and improving airway patency and abdominal discomfort during acute attacks.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: discomfort at the site of subcutaneous administration. - Erythema: redness around the injection area. - Local swelling: mild edema at the injection site. - Pruritus: itching at or near the injection site. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema of the face or throat: potentially life‑threatening swelling. - Hypotension: sudden drop in blood pressure. - Severe hypersensitivity: widespread rash or hives. - Rare thrombotic events: clot formation in blood vessels.

When using Icatibant, several safety considerations should be observed to minimize risk.

Allergy assessment: verify no known hypersensitivity to Icatibant or its excipients. Pregnancy: safety has not been established; use only if potential benefit outweighs risk. Breastfeeding: unknown safety; caution advised. Renal impairment: consider dose adjustment and monitor response. Concomitant ACE inhibitor therapy: increased bradykinin levels may heighten risk of angioedema; monitor closely. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence the bradykinin system or affect hemodynamic stability.

Major Interactions (Avoid): - ACE inhibitors: may amplify bradykinin‑mediated angioedema. - Neprilysin inhibitors (e.g., sacubitril): increase bradykinin levels, raising risk of swelling. - Other bradykinin B2 receptor agonists: antagonistic competition can reduce efficacy.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may modestly increase angioedema risk. - Other HAE therapies (e.g., C1‑esterase inhibitor concentrates): overlapping effects on edema control. - NSAIDs: potential to exacerbate hypersensitivity reactions. - Diuretics: may affect fluid balance and blood pressure, requiring observation.